Skip to main content
PLOS One logoLink to PLOS One
. 2025 Dec 4;20(12):e0337593. doi: 10.1371/journal.pone.0337593

The impact of Traditional Chinese Medicine utilization on life expectancy and mortality

Jui-Yi Wang 1, Hsien-Chang Wu 2,3, Jing-Shiang Hwang 4, Wei-Cheng Lo 1,5,*
Editor: Yung-Hsiang Chen6
PMCID: PMC12677513  PMID: 41343522

Abstract

Purpose

Traditional Chinese Medicine (TCM) is extensively utilized in Asian societies and has shown potential benefits in improving survival rates of patient with specific diseases and anti-aging effects. However, its impact on life expectancy of general population remains relatively unexplored. This study aimed to investigate the impact of TCM utilization on mortality risk and life expectancy in Taiwan.

Methods

A nationwide longitudinal cohort study was conducted using data from the Taiwan National Health Interview Survey linked with the National Health Insurance Research Database. Cox proportional hazard models were used to calculate the risk of all-cause mortality between frequent TCM users (≥20% of outpatient visits) and non-frequent users (<20%). A rolling extrapolation algorithm was used to estimate lifetime survival functions, and inverse probability of treatment weighting was integrated to adjust for confounding variables.

Results

The study included 12,176 participants (1,596 frequent TCM users and 10,580 non-frequent TCM users) aged ≥55 years, with a median follow-up duration of 10.49 years. After adjustment for confounding factors, frequent TCM users had a longer life expectancy compared to non-frequent TCM users, with a difference of 1.37 years (95% CI: 0.22–3.32). Higher TCM utilization was associated with reduced mortality risk (HR: 0.89, 95% CI: 0.80–0.99). Results remained consistent across dose-response analysis and time-dependent exposure models.

Conclusions

This study suggests that higher TCM utilization is associated with longer life expectancy and lower mortality risk among older adults in Taiwan. Further studies are warranted to clarify potential mechanisms and to explore how TCM utilization may complement conventional healthcare in addressing the needs of aging populations.

Background

Traditional Chinese Medicine (TCM) is widely utilized across Asian societies for both daily health maintenance and the treatment of various medical conditions [15]. TCM encompasses practices such as Chinese herbal medicine, acupuncture, and manipulative treatments, and is a cornerstone of complementary and alternative medicine therapies. In countries like Taiwan, Japan, Korea, and China, TCM has been institutionalized to a degree nearly equivalent to that of conventional Western medicine [6,7]. Practitioners are officially certified and regulated, and expenses related to TCM therapies are covered by national health insurance schemes [810].

As an integrative treatment approach, TCM has been suggested to provide potential benefits in improving patient survival rates and anti-aging effects. Multiple observational studies have found that combining standard Western medical treatments, such as surgery and chemotherapy, with adjunctive TCM therapies associated with reduced mortality risk among patients with advanced breast, gastric, lung, and liver cancers [1116]. Additionally, recent studies have suggested that Chinese herbal medicines or their active components may delay aging and prevent age-related diseases [17,18]. Polysaccharides, monopolysaccharides, and sesquiterpenes in TCM have been reported to exhibit anti-inflammatory, antitumor, antiviral, and sedative effects, making them potential sources for the development of anti-aging drugs [19,20].

Nevertheless, the impact of TCM utilization on life expectancy (LE) of general population has been relatively underexplored. One study has evaluated the Chinese healthcare system reform utilized ecological level data to investigate the impacts of TCM on population health outcomes and medical expenditures [21]. The analysis revealed that an increase of one TCM physician per 100,000 population was associated with a reduction of 1.944 excess deaths, an increase of 5.84 days in male LE, and a decrease of 0.051% in average medical expenditures among both urban and rural residents. However, the use of the number of TCM physicians as a proxy for TCM exposure may introduce bias, and the ecological analysis design could result in numerous individual-level confounders not being adequately accounted for.

The principle of TCM treatment is to enable the body to reach a state of normal harmony through drug treatment, emphasizing the strengthening of the body’s inherent immunity to cure diseases and providing individualized and precise treatment. The World Health Organization (WHO) has underscored the significance of traditional medicine and has appealed for global policies to support its development, as outlined in the WHO Traditional Medicine Strategy 2014–2023 [22]. Therefore, to quantify the impact of TCM utilization on overall health and LE will serve as empirical support for promoting the use of TCM and the development of TCM-based drugs. The objective of this study is to investigate the impact of TCM utilization on mortality risk and LE in Taiwan. Using a nationally representative cohort with over 10,000 participants, a rolling extrapolation algorithm was applied to estimate the lifetime survival function and LE of comparative study cohorts of frequent and non-frequent TCM users.

Methods

Study design, settings, and population

A nationwide longitudinal cohort study was conducted. We used data from the Taiwan National Health Interview Survey (NHIS) linked with the National Health Insurance Research Database (NHIRD) to determine participants’ utilization of TCM services. The study sample comprised individuals who participated in the Taiwan NHIS in 2001, 2005, 2009, and 2013, with response rates of 93.8%, 80.6%, 84.0%, and 75.2%, respectively [23]. The NHIS is a cross-sectional survey that adopted a multistage stratified sampling scheme to obtain a nationally representative sample of the Taiwanese population. Baseline data on participants’ sociodemographic and behavioral factors were collected through in-person interviews. Details of the NHIS design and sampling scheme have been previously reported [24]. Participants were classified as frequent TCM users if outpatient visits for TCM services, including Chinese herbal formula, acupuncture, and remedial massage (Tuina), accounted for more than 20% of their total outpatient visits during the 18 months preceding the baseline. Those whose TCM visits constituted 20% or less were classified as non-frequent TCM users. Based on national health insurance data, TCM typically accounts for about 10% of outpatient visits in Taiwan, indicating most individuals use it occasionally [25]. We therefore used a conservative 20% threshold to identify those for whom TCM constitutes a relatively frequent and substantial part of their healthcare use. A total of 20,898 participants aged 55 years and older were initially included. Exclusions were made for participants who refused to link their NHIS data to NHIRD records (n = 3,251), those with a history of cancer (n = 958) or autoimmune rheumatic disease and other rare disease (n = 866) or, those with no healthcare utilization record or fewer than five medical visits in the past year and a half before baseline (n = 1,598), and those with missing covariate data (n = 2,049). The final analytical sample included 12,176 participants at baseline, comprising 1,596 frequent TCM users and 10,580 non-frequent TCM users. Participants were followed until the end of the study period (December 31, 2020) or until death, as confirmed by data from Taiwan’s vital registry (Fig 1). The data were accessed for research purposes from 6th August 2023–24th October 2024. This study was approved by the Taipei Medical University-Joint Institutional Review Board (TMU-JIRB- N202304099). All human research was conducted according to the Declaration of Helsinki. Because the database contains only deidentified data, the IRB waived the requirement for written informed consent.

Fig 1. Flowchart of the study population selection.

Fig 1

NHIS: National Health Interview Survey; NHIRD: National Health Insurance Research Database; TCM: Traditional Chinese Medicine.

Covariates

We obtained study participants’ sociodemographic characteristics and lifestyle factors from the NHIS database, and their baseline disease history from the NHIRD. The NHIS data collection involved in-person interviews and structured questionnaire survey [24]. We accounted for various potential confounders and covariates, including year of enrollment, baseline age, sex, education level, marital status, monthly household income, employment status, BMI, smoking habits, alcohol consumption, betel nut use, leisure-time physical activity, and adequate intake of fruits and vegetables. Additionally, we included baseline disease history such as cardiovascular disease, diabetes mellitus, chronic lung diseases (asthma or chronic obstructive pulmonary disease), chronic kidney diseases, chronic liver disease, and dementia (S1 Table and S1 File).

Statistical analysis

Despite a median follow-up duration of 10.49 years, a significant proportion of participants remained alive by the end of follow-up. A rolling extrapolation algorithm can be used to estimate the lifetime survival function of study cohorts [26]. This extrapolation method has been successfully implemented in many studies to estimate the loss or gain of LE in cohorts with specific health conditions and exposures [2730]. LE for each study cohort was derived by integrating the corresponding extrapolated lifetime survival function. To make a fair comparison of LE between the comparative cohorts of frequent and non-frequent TCM users, we used an inverse probability of treatment weighting (IPTW) approach to adjust for confounding variables which could influence both utilization of TCM and LE. That is, we first calculated the propensity score for each participant, which is the estimated probability of being in a particular cohort based on a logistic regression model. We then assigned each individual a weight, which is the inverse of their propensity score, to create two weighted cohorts or cohorts of weighted samples. To prevent extreme weights from disproportionately influencing the results, values below the 1st percentile and above the 99th percentile were truncated to the corresponding cutoff values. Next, we applied the rolling extrapolation algorithm to the weighted survival times to obtain lifetime survival functions for the two weighted groups [31,32]. We calculated standardized mean difference (SMD) of the covariates between the two groups of weighted samples to assess balance of covariates in the two groups, with SMD < 0.1 indicating an acceptable balance. The difference in LE between the two weighted cohorts represented the estimated LE difference attributable to differential levels of TCM utilization. All estimates, standard errors, and 95% confidence intervals (CIs) were obtained using the R package iSQoL2, which can be downloaded from here: http://sites.stat.sinica.edu.tw/isqol/.

To assess the differential mortality risk between frequent and non-frequent TCM users, we used Cox proportional hazard models to calculate adjusted hazard ratios (HRs) and corresponding 95% CIs for all-cause mortality associated with TCM utilization. A series of sensitivity analyses were conducted to examine the robustness of results under varying exposure definition. First, we treated TCM utilization as continuous variable, quantified by the percentage of outpatient visits for TCM services relative to total outpatient visits in the 18 months preceding the baseline. Subsequently, we stratified TCM utilization into four distinct categories based on the proportion of TCM-related outpatient visits: < 10%, 10–20%, 20–30%, and >30%. Moreover, to account for the dynamic nature of TCM utilization, we implemented a time-dependent variable approach. In this time-dependent Cox model, annual TCM utilization was defined as the proportion of TCM outpatient visits relative to total outpatient visits in the preceding year. This variable was updated each year during follow-up to reflect temporal changes in individual patterns of TCM use, allowing a more precise analysis of its association with mortality risk. These models were adjusted for the effects of the aforementioned covariates. Statistical significance was set at a 2-tailed value of P < 0.05.

Results

Baseline characteristics

The characteristics of the study participants, a total of 12,176 individuals, including 1,596 frequent TCM users and 10,580 non-frequent TCM users, are shown in Table 1. The mean age for frequent TCM users was 64.1 ± 7.7 years, compared to 67.1 ± 8.9 years for non-frequent TCM users. Females comprised 58.2% of the frequent TCM user group and 49.7% of the non-frequent TCM user group. Frequent TCM users were more likely to be married, possess higher educational attainment, report lower household income levels, and less unemployed. Regarding lifestyle behaviors, frequent TCM users were less likely to engage in smoking, alcohol consumption, and betel nut use, and more inclined to participate in regular leisure-time physical activity and maintain adequate vegetable and fruit intake. The mean BMI was 23.9 ± 3.3 kg/m² for frequent TCM users and 24.5 ± 3.6 kg/m² for non-frequent TCM users. Additionally, the prevalence of cardiovascular disease, diabetes mellitus, and chronic lung diseases, chronic liver disease, and dementia was lower among frequent TCM users. After the IPTW adjustment, the participants’ characteristics between the frequent and non-frequent TCM users were well balanced with a SMD < 0.1 (Table 1).

Table 1. Baseline demographic and lifestyle characteristics of study population before and after the IPTW adjustment.

Before IPTW After IPTW
Frequent TCM user Non-frequent TCM user Frequent TCM user Non-frequent TCM user
N 1596 10580 12305.1 12174.6
Demographic characteristics N (%) N (%) SMD P-value N (%) N (%) SMD P-value
Age, Mean (SD) 64.1 (7.7) 67.1 (8.9) 0.360 <0.0001 66.7 (8.8) 66.8 (8.7) 0.005 0.879
Age group 0.339 <0.0001 0.024 0.894
 55–59 yrs 593 (37.1) 2772 (26.2) 3330.4 (27.1) 3364.3 (27.6)
 60–69 yrs 652 (40.9) 3993 (37.7) 4642.1 (37.7) 4643.1 (38.1)
 70–79 yrs 270 (16.9) 2748 (26.0) 3179.9 (25.8) 3018.9 (24.8)
 80+ 81 (5.1) 1067 (10.1) 1152.7 (9.4) 1148.2 (9.4)
Sex 0.171 <0.0001 0.006 0.833
 Male 668 (41.8) 5325 (50.3) 6095.5 (49.5) 5991.4 (49.2)
 Female 928 (58.2) 5255 (49.7) 6209.6 (50.5) 6183.2 (50.8)
Education 0.153 <0.0001 0.018 0.825
 Less than elementary school 920 (57.6) 6884 (65.1) 7993.0 (65.0) 7805.4 (64.1)
 High school 464 (29.1) 2571 (24.3) 2991.5 (24.3) 3031.7 (24.9)
 College or above 212 (13.3) 1125 (10.6) 1320.6 (10.7) 1337.4 (11.0)
Marriage 0.049 0.1961 0.012 0.925
 Married/cohabiting 1202 (75.3) 7787 (73.6) 9144.2 (74.3) 8988.2 (73.8)
 Never married 34 (2.1) 198 (1.9) 237.3 (1.9) 231.2 (1.9)
 Others* 360 (22.6) 2595 (24.5) 2923.5 (23.8) 2955.1 (24.3)
Household income# 0.138 <0.0001 0.017 0.856
 Low 390 (24.4) 2371 (22.4) 2747.9 (22.3) 2762.4 (22.7)
 Median 689 (43.2) 4086 (38.6) 4767.1 (38.7) 4771.8 (39.2)
 High 517 (32.4) 4123 (39.0) 4790.1 (38.9) 4640.4 (38.1)
Employment status 0.111 <0.0001 0.014 0.665
 Employed (included homemaker & retired) 1349 (84.5) 8495 (80.3) 9878.3 (80.3) 9842.5 (80.8)
 Unemployed 247 (15.5) 2085 (19.7) 2426.7 (19.7) 2332.1 (19.2)
Lifestyle factors
Cigarette smoking 0.188 <0.0001 0.017 0.882
 Never smokers 1264 (79.2) 7525 (71.1) 8804.6 (71.6) 8787.2 (72.2)
 Former smokers 131 (8.6) 1274 (12.1) 1425.1 (11.6) 1410.0 (11.6)
 Current smokers 195 (12.2) 1781 (16.8) 2075.3 (16.9) 1977.3 (16.2)
Alcohol use 0.099 0.0113 0.019 0.950
 Nonconsumers 1019 (63.8) 6811 (64.4) 7893.5 (64.1) 7828.3 (64.3)
 Infrequent consumers 410 (25.7) 2506 (23.7) 2913.2 (23.7) 2915.4 (23.9)
 Regular consumers 156 (9.8) 1089 (10.3) 1285.8 (10.4) 1245.7 (10.2)
 Excess consumers 11 (0.7) 174 (1.6) 212.6 (1.7) 185.1 (1.5)
Betel nut use 0.101 0.0023 0.018 0.878
 Never user 1490 (93.4) 9619 (90.9) 11220.0 (91.2) 11107.8 (91.2)
 Former user 67 (4.2) 533 (5.0) 642.2 (5.2) 600.0 (4.9)
 Current user 39 (2.4) 428 (4.1) 442.8 (3.6) 466.8 (3.8)
Leisure-time physical activity 0.106 0.0001 0.013 0.665
 Yes 991 (62.1) 6018 (56.9) 7001.8 (56.9) 7008.7 (57.6)
 No 605 (37.9) 4562 (43.1) 5303.3 (43.1) 5165.9 (42.4)
Adequate intake of vegetables 0.083 0.0031 0.026 0.452
 Yes 1492 (93.5) 9657 (91.3) 11174.3 (90.8) 11146.9 (91.6)
 No 104 (6.5) 923 (8.7) 1130.8 (9.2) 1027.7 (8.4)
Adequate intake of fruits 0.136 <0.0001 0.023 0.485
 Yes 1200 (75.2) 7309 (69.1) 8471.5 (68.8) 8509.2 (69.9)
 No 396 (24.8) 3271 (30.9) 3833.6 (31.2) 3665.3 (30.1)
BMI group 0.172 <0.0001 0.017 0.959
 Underweight (BMI < 18.5 kg/m2) 66 (4.1) 351 (3.3) 398.0 (3.2) 415.7 (3.4)
 Normal weight (18.5 ≤ BMI < 25 kg/m2) 1011 (63.4) 5963 (56.4) 7130.0 (57.9) 6975.2 (57.3)
 Overweight (25 ≤ BMI < 30 kg/m2) 447 (28.0) 3538 (33.4) 3999.5 (32.5) 3983.8 (32.7)
 Obese (BMI ≥ 30 kg/m2) 72 (4.5) 728 (6.9) 777.6 (6.3) 799.8 (6.6)
Comorbid diseases
 Cardiovascular disease 652 (40.8) 6226 (58.9) 0.366 <0.0001 7029.0 (57.1) 6877.8 (56.5) 0.013 0.665
 Diabetes mellitus 196 (12.3) 2253 (21.3) 0.243 <0.0001 2667.4 (21.7) 2450.6 (20.1) 0.038 0.283
 Chronic lung diseases 88 (5.5) 862 (8.2) 0.105 0.0003 889.5 (7.2) 949.5 (7.8) 0.022 0.521
 Chronic kidney diseases 32 (2.0) 257 (2.4) 0.029 0.2995 300.6 (2.4) 289.1 (2.4) 0.004 0.892
 Chronic liver disease 117 (7.3) 958 (9.1) 0.063 0.0236 1206.2 (9.8) 1075.9 (8.8) 0.033 0.330
 Dementia 16 (1.0) 206 (2.0) 0.078 0.0086 280.7 (2.3) 222.5 (1.8) 0.032 0.412

IPTW: inverse probability of treatment weighting; SMD: standardized mean difference.

* Others: widowed, divorced, separated, or serving as a single parent.

# Household income (US dollars per month): low: < $980; median: $980 to $3260; high: > $3260.

Impact on life expectancy

Using the rolling extrapolation method, we estimated the lifetime survival curves for the weighted cohorts of frequent and non-frequent TCM user (Fig 2). Based on the extrapolated survival curves from the original samples, we estimated a LE of 21.7 years (95% CI: 19.1–23.4) for frequent TCM users with a mean age of 64.1 years, and 17.6 years (95% CI: 17.0–18.1) for non-frequent TCM users with a mean age of 67.1 years. Crude estimates suggested a slightly longer expected lifespan among frequent TCM users (85.8 vs. 84.7 years). After adjustment for potential confounders using weighted samples, frequent TCM users showed a longer LE compared to non-frequent TCM users, with a difference of 1.37 years (95% CI: 0.22–3.32, p < 0.05) (Table 2). Stratified analyses revealed that among males, frequent TCM users had a 2.39-year higher LE compared to non-frequent TCM users (95% CI: 0.27–4.21, p = 0.02), whereas among females, frequent TCM users had a 1.22-year lower LE, though not statistically significant (95% CI: −3.49–1.29, p = 0.33). When stratifying by smoking status, current or former smokers who were frequent TCM users had a significantly longer LE than non-frequent TCM users (3.31 years, 95% CI: 0.07–6.41, p = 0.04). However, no significant difference was found among never-smokers (LE difference: 0.35 years, 95% CI: −2.32–2.57, p = 0.79). Similar patterns were observed when stratifying by alcohol use. Among drinkers, frequent TCM users showed a longer LE compared to non-frequent TCM users, although this difference did not reach statistical significance (LE difference: 2.81 years, 95% CI: −1.49–5.41, p = 0.13).

Fig 2. IPTW-weighted lifetime survival function of frequent and non-frequent TCM user cohorts.

Fig 2

The frequent TCM user group (red dashed line) exhibits longer survival times compared to the non-frequent TCM user group (black solid line). The vertical black dotted line stands for the starting month of extrapolation. TCM: Traditional Chinese Medicine.

Table 2. Life expectancy and years of life gained of frequent and non-frequent TCM user cohorts.

Frequent TCM user Non-frequent TCM user
Strata LE (95%CI) LE (95%CI) Years of life gained(95%CI)
Overall
 IPTW adjustment 19.25 (17.96, 21.07) 17.88 (17.25, 18.42) 1.37 (0.22, 3.32)
Sex
 Male 18.87 (16.90, 20.82) 16.48 (15.74, 17.18) 2.39 (0.27, 4.21)
 Female 18.32 (16.21, 20.40) 19.54 (18.41, 20.55) −1.22 (−3.49, 1.29)
BMI group
 BMI < 25 kg/m2 18.92 (16.92, 20.90) 17.77 (17.02, 18.48) 1.15 (−1.00, 3.55)
 BMI>=25 kg/m2 19.91 (16.70, 22.91) 18.00 (17.11, 19.20) 1.91 (−1.47, 4.52)
Cigarette smoking
 Never smokers 19.39 (17.13, 21.59) 19.04 (18.19, 19.93) 0.35 (−2.32, 2.57)
 Current or former smokers 18.48 (15.20, 21.62) 15.17 (14.56, 15.79) 3.31 (0.07, 6.41)
Alcohol use
 Nonconsumers 18.42 (16.53, 20.58) 17.19 (16.56, 18.17) 1.23 (−0.81, 3.82)
 Drinkers* 22.34 (18.12, 24.33) 19.53 (18.08, 20.50) 2.81 (−1.49. 5.41)
Leisure-time physical activity
 Yes 20.62 (18.28, 22.36) 18.84 (17.93, 19.63) 1.78 (−0.43, 3.78)
 No 18.12 (15.33, 20.64) 16.71 (15.92, 17.59) 1.41 (−1.50, 3.83)
Adequate intake of vegetables and fruits#
 Yes 20.61 (18.32, 22.43) 19.43 (18.45, 20.25) 1.18 (−1.20, 3.40)
 No 16.31 (13.38, 18.14) 15.54 (14.77, 16.65) 0.77 (−2.12, 2.65)

LE: Life expectancy; IPTW: inverse probability of treatment weighting

* Including infrequent, regular, and excess consumers.

# The intake of both vegetables and fruits is adequate.

Traditional Chinese medicine utilization and mortality risk

During the follow-up period, a total of 4,023 deaths were recorded. In Cox regression model adjusting for age, sex, enrollment year, education level, marital status, monthly household income, employment status, lifestyle factors, and comorbid diseases, frequent TCM user was associated with a modestly lower risk of all-cause mortality, with a HR of 0.89 (95% CI, 0.80–0.99) (Table 3). Dose-response analyses suggested a trend toward reduced mortality risk with higher TCM utilization, though not all categories reached statistical significance. After covariate adjustment, compared to TCM utilization of less than 10%, the HRs for TCM utilization of 10–20%, 20–30%, and greater than 30% were 0.89 (95% CI, 0.79–1.01), 1.01 (95% CI, 0.86–1.12), and 0.81 (95% CI, 0.71–0.93), respectively.

Table 3. Hazard Ratios (HRs) and 95% CIs for associations between TCM utilization and all-cause mortality risk.

Model 1a Model 2b
TCM utilization Deaths Person-years HR (95%CI) HR (95%CI)
Frequent TCM user vs. non-frequent user
 Non-frequent TCM user 3651 109201.7 1.00 1.00
 Frequent TCM user 372 17425.7 0.80 (0.72, 0.89) 0.89 (0.80, 0.99)
% of TCM utilization (categorical)
  < 10% 3383 98222.9 1.00 1.00
 10-20% 268 10978.8 0.86 (0.76, 0.97) 0.89 (0.79, 1.01)
 20-30% 151 5846.7 0.96 (0.81, 1.12) 1.01 (0.86, 1.12)
  ≥ 30% 221 11579.0 0.71 (0.62, 0.81) 0.81 (0.71, 0.93)
% of TCM utilization (continuous)
 per 10% of TCM utilization increase (baseline) 4023 126627.4 0.94 (0.92, 0.97) 0.98 (0.95, 1.01)
 per 10% of TCM utilization increase (time-varying) 4023 126627.4 0.93 (0.92, 0.94) 0.95 (0.94, 0.96)

aModel 1 adjusted for age, sex, enrolment year, education level, marital status, monthly household income, and employment status.

bModel 2 adjusted for age, sex, enrolment year, education level, marital status, monthly household income, employment status, lifestyle factors, and medical history of cardiovascular disease, diabetes mellitus, chronic lung diseases, chronic kidney diseases, chronic liver disease, and dementia.

When TCM utilization was treated as a continuous variable using two distinct exposure time windows, either the baseline window (18 months preceding the baseline) or as time-dependent (updated TCM exposure annually). For every 10% increase in TCM utilization at baseline, the HR for all-cause mortality was 0.98 (95% CI, 0.95–1.01). Consistent associations were observed in the time-dependent analysis, with an HR of 0.95 (95% CI, 0.94–0.96) per 10% increase in TCM utilization (Table 3). Additional analyses examining incidence of major chronic diseases yielded results generally consistent with the observed associations for mortality risk (S2 and S3 Tables).

Discussion

To the best of our knowledge, this is the first study to evaluate the association of TCM utilization with LE and mortality risk in the general population using individual-level empirical data. Our findings suggest that frequent TCM use was associated with modestly increased LE and reduced mortality risk, with a difference of 1.37 years in LE and a HR of 0.89 (95% CI, 0.80–0.99) compared to non-frequent TCM users. These results were generally consistent across various analytical approaches, including binary and multi-categorical exposure classification, dose-response analysis, and time-dependent exposure models, thus strengthening the robustness of our findings.

The observed association aligns with previous research, indicating potential benefits of TCM for specific health conditions and its anti-aging properties. A longitudinal study conducted by Li et al. on 1,988 patients with advanced lung adenocarcinoma reported that subjects utilizing Chinese herbal medicine as an adjuvant to tyrosine kinase inhibitor (TKI) treatment for ≥180 days exhibited significantly reduced mortality rates and improved overall and progression-free survival [33]. Additionally, a large-scale retrospective study in Taiwan, encompassing 79,335 breast cancer patients, suggested a dose-dependent protective effect associated with prolonged use of Danshen (Salvia miltiorrhiza) [34]. Kuo et al. performed a comprehensive analysis of 582,799 adult cancer patients in Taiwan, revealing significantly lower mortality risk among TCM users compared to non-users [35]. Moreover, a real-world study focusing on liver cancer treatment identified Jiawei Xiaoyao San and Chaihu Shugan Decoction as the most efficacious Chinese herbal formulas for improving overall survival [36]. On the other hand, preclinical studies have also elucidated TCM’s considerable anti-aging potential, primarily through its anti-inflammatory actions, enhancement of intestinal health, and maintenance of telomere integrity. TCM has been suggested to help address age-related pathologies, including diabetes, neurodegenerative disorders, cardiovascular diseases, and various malignancies, by modulating multiple biological pathways [37]. While these findings are suggestive, the precise mechanisms underlying these effects and the specific impacts of various TCM interventions necessitate further rigorous investigation.

TCM offers a unique advantage in promoting health and treating diseases through its deeply personalized approach, which could potentially contribute to more favorable health outcomes than standardized treatments. Rooted in a holistic perspective, TCM views the human body as a dynamic system seeking Yin-Yang balance [38]. At its core, TCM employs the concept of “Treatment of Differential Syndrome” (TDS), recognizing each patient as a unique individual with specific imbalances and needs [39]. Unlike the often-standardized treatments in Western medicine, TCM practitioners meticulously analyze symptoms and signs to determine a patient’s syndrome, considering not only physical manifestations but also genetic, physiological, psychological, spiritual, and social dimensions. This comprehensive assessment enables highly tailored treatments that address root causes rather than merely alleviating symptoms. TCM’s combinatorial formulae, synergistically blending multiple herbs and components, are customized based on the patient’s specific syndrome and physique characteristics. This personalized approach extends beyond treating diseases to include early intervention and management of sub-healthy states, emphasizing prevention and overall well-being [40]. By focusing on restoring balance to the entire body system and adapting treatments to the individual’s changing needs over time, TCM embodies many principles now emphasized in modern precision and personalized medicine.

In this study, we used the frequency of TCM utilization as a proxy indicator for exposure to TCM practices. This approach not only represents the degree of engagement with TCM but also suggests that higher-frequency TCM users may be more likely to embrace the principles of TCM in disease treatment and health promotion. A knowledge, attitude, and practice survey conducted in Shanghai, focusing on the elderly population, corroborated this notion by demonstrating a strong consistency between cognitive understanding and behavioral practices in the utilization of traditional medicine [41]. TCM users were more likely to possess a heightened health consciousness and pursue a more health-oriented lifestyle, as presented by the differences observed in baseline characteristics between frequent and non-frequent TCM users in our study. Given the rapid demographic transition and the growing prevalence of multimorbidity, understanding how holistic care models such as TCM can complement conventional medicine is increasingly important. The TCM perspective, which emphasizes mind-body balance and integrative health, offers a useful framework for addressing the complex interplay among chronic diseases and their cumulative effects on quality of life in older adults [38,42]. This multidimensional view may help advance a more integrated and person-centered approach to managing multimorbidity. In Asia, the belief in and use of traditional medicine are deeply rooted in cultural and spiritual foundations [43]. However, despite its long-standing history, the empirical evidence base for TCM’s population-level effects remains limited [44]. Through the use of real-world longitudinal data and a rigorous research design, this study provides insights into the relationship between TCM utilization and overall health outcomes, providing a reference for future research and the potential role of traditional medicine within modern healthcare systems.

Strengths and limitations

Our study’s strengths lie in its methodological rigor and comprehensive approach. We utilized a large, nationally representative sample with prospective design and near-complete follow-up. The integration of survey data with National Health Insurance claims and vital registry records provided an opportunity to investigate the relationship between TCM utilization on LE in Taiwan. The extrapolation of lifetime survival functions, combined with IPTW adjustment, enhanced the robustness and validity of our findings. Several limitations should be acknowledged. First, all analyzed covariates were assessed only at baseline; therefore, changes in these factors over time could not be accounted for, as no repeated measurement data were available. Second, although the models were adjusted for a wide range of demographic, socioeconomic, lifestyle, and health-related variables, the possibility of residual or unmeasured confounding effects cannot be ruled out. TCM users may differ from non-users in health awareness, social support, or health-seeking behaviors that were not fully measured. In addition, regular contact with TCM practitioners may provide non-specific benefits, such as health advice or stress reduction, which are independent of the specific pharmacological or procedural effects of TCM. Third, this study did not differentiate in detail between various types of TCM utilization, such as Chinese herbal formula, acupuncture, and remedial massage (Tuina); therefore, the observed associations should be interpreted as reflecting overall TCM service utilization rather than the effects of specific treatment types. We also acknowledge that the available data do not allow us to determine whether the 20% threshold used to define frequent TCM use represents an optimal cutoff across different populations or health conditions, nor whether it holds equivalent meaning across various TCM modalities. Further studies using more detailed information on TCM use may better define treatment patterns and identify suitable thresholds for frequent use. Fourth, the dose–response analysis assumed a linear association between the proportion of TCM use and mortality risk. Although this approach facilitated interpretation, potential nonlinear patterns such as threshold or plateau effects were not assessed. Future studies applying flexible models, such as restricted cubic splines, may help clarify the functional form of this relationship. Lastly, while healthcare services in Taiwan, including TCM, have a high coverage rate, this study could not evaluate whether participants engaged in other forms of traditional or folk medicine, which may have influenced the outcomes.

Conclusions

Our study observed an association between TCM use and longer life expectancy, along with a lower risk of all-cause mortality. These associations were consistent across multiple analytical approaches, supporting the robustness of the findings. However, causal inference cannot be established due to the observational study design. The observed associations may reflect not only the effects of TCM utilization but also characteristics of TCM users, the healthcare context, and possible holistic benefits associated with regular engagement with TCM. Our findings provide population-level insights that can inform future studies on TCM’s potential role in promoting healthy aging, improving quality of life, and supporting integrated healthcare approaches. While further research is needed to clarify the underlying mechanisms, refine exposure definitions, and account for unmeasured behavioral or psychosocial factors, this study offers a foundation for understanding the potential contribution of TCM as a complementary component of comprehensive healthcare strategies.

Supporting information

S1 File. Supplementary methods.

(PDF)

pone.0337593.s001.pdf (141.1KB, pdf)
S1 Table. ICD codes for baseline comorbidities.

(PDF)

pone.0337593.s002.pdf (54.7KB, pdf)
S2 Table. Hazard Ratios (HRs) and 95% CIs for associations between TCM utilization (frequent user vs. non-frequent user) and risk of major chronic diseases development.

(PDF)

pone.0337593.s003.pdf (127.7KB, pdf)
S3 Table. Hazard Ratios (HRs) and 95% CIs for associations between TCM utilization (per 10% of TCM utilization increase) and risk of major chronic diseases development.

(PDF)

pone.0337593.s004.pdf (121.3KB, pdf)
S1 Data. STROBE checklist cohort.

(DOC)

pone.0337593.s005.doc (95.5KB, doc)

Acknowledgments

We thank Ms. Tsuey-Hwa Hu from the Institute of Statistical Science at Academia Sinica for her professional statistical recommendations and support on this work.

Data Availability

The data used in this analysis are not owned by the authors and therefore cannot be shared publicly. To acquire access to the individual-level data, interested researchers must complete an application form, submit a research proposal, and provide documentation of institutional review board approval to the Health and Welfare Data Science Center, Taiwan (https://dep.mohw.gov.tw/DOS/cp-5119-59201-113.html). The Center will review these materials and grant access to eligible researchers who meet the criteria for accessing confidential data. It should be noted that authorized researchers will be granted access to the data under the same conditions and procedures as the authors.

Funding Statement

This work was supported by the National Science and Technology Council (Grant number: NSTC112-2314-B-038-073-MY3) in Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

References

  • 1.Mukherjee PK. Evaluation of Indian Traditional Medicine. Drug Inf J. 2001;35(2):623–32. doi: 10.1177/009286150103500235 [DOI] [Google Scholar]
  • 2.Ock SM, Choi JY, Cha YS, Lee J, Chun MS, Huh CH, et al. The use of complementary and alternative medicine in a general population in South Korea: results from a national survey in 2006. J Korean Med Sci. 2009;24(1):1–6. doi: 10.3346/jkms.2009.24.1.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Peltzer K, Pengpid S. Utilization and Practice of Traditional/Complementary/Alternative Medicine (T/CAM) in Southeast Asian Nations (ASEAN) Member States. Stud Ethno-Med. 2015;9(2):209–18. doi: 10.1080/09735070.2015.11905437 [DOI] [Google Scholar]
  • 4.Thompson CM. Vietnamese traditional medicine: a social history. NUS Press; 2015. [Google Scholar]
  • 5.Yamashita H, Tsukayama H, Sugishita C. Popularity of complementary and alternative medicine in Japan: a telephone survey. Complement Ther Med. 2002;10(2):84–93. doi: 10.1054/ctim.2002.0519 [DOI] [PubMed] [Google Scholar]
  • 6.Hesketh T, Zhu WX. Health in China. Traditional Chinese medicine: one country, two systems. BMJ. 1997;315(7100):115–7. doi: 10.1136/bmj.315.7100.115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Park H-L, Lee H-S, Shin B-C, Liu J-P, Shang Q, Yamashita H, et al. Traditional medicine in china, Korea, and Japan: a brief introduction and comparison. Evid Based Complement Alternat Med. 2012;2012:429103. doi: 10.1155/2012/429103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chang L-C, Huang N, Chou Y-J, Lee C-H, Kao F-Y, Huang Y-T. Utilization patterns of Chinese medicine and Western medicine under the National Health Insurance Program in Taiwan, a population-based study from 1997 to 2003. BMC Health Serv Res. 2008;8:170. doi: 10.1186/1472-6963-8-170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Jin L. From mainstream to marginal? Trends in the use of Chinese medicine in China from 1991 to 2004. Soc Sci Med. 2010;71(6):1063–7. doi: 10.1016/j.socscimed.2010.06.019 [DOI] [PubMed] [Google Scholar]
  • 10.Takayama S, Iwasaki K. Systematic review of traditional Chinese medicine for geriatrics. Geriatr Gerontol Int. 2017;17(5):679–88. doi: 10.1111/ggi.12803 [DOI] [PubMed] [Google Scholar]
  • 11.Lee Y-W, Chen T-L, Shih Y-RV, Tsai C-L, Chang C-C, Liang H-H, et al. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer. 2014;120(9):1338–44. doi: 10.1002/cncr.28579 [DOI] [PubMed] [Google Scholar]
  • 12.Liao Y-P, Kung P-T, Wang Y-H, Chu Y-R, Kao S-T, Tsai W-C. Effects and relative factors of adjunctive Chinese Medicine Therapy on survival of hepatocellular carcinoma patients: a retrospective cohort study in Taiwan. Integr Cancer Ther. 2020;19. doi: 10.1177/1534735420915275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lin G, Li Y, Chen S, Jiang H. Integrated Chinese-western therapy versus western therapy alone on survival rate in patients with non-small-cell lung cancer at middle-late stage. J Tradit Chin Med. 2013;33(4):433–8. doi: 10.1016/s0254-6272(13)60144-2 [DOI] [PubMed] [Google Scholar]
  • 14.Liu X, Li M, Wang X, Dang Z, Yu L, Wang X, et al. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine. 2019;62:152930. doi: 10.1016/j.phymed.2019.152930 [DOI] [PubMed] [Google Scholar]
  • 15.Shih W-T, Yang P-R, Shen Y-C, Yang Y-H, Wu C-Y. Traditional Chinese Medicine enhances survival in patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: A Nationwide Matched Cohort Study. Evid Based Complement Alternat Med. 2021;2021:7584631. doi: 10.1155/2021/7584631 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Yeh M-H, Wu H-C, Lin N-W, Hsieh J-J, Yeh J-W, Chiu H-P, et al. Long-term use of combined conventional medicine and Chinese herbal medicine decreases the mortality risk of patients with lung cancer. Complement Ther Med. 2020;52:102427. doi: 10.1016/j.ctim.2020.102427 [DOI] [PubMed] [Google Scholar]
  • 17.Ning Z, Li Y, Liu D, Owoicho Orgah J, Zhu J, Wang Y, et al. Tetrahydroxystilbene glucoside delayed senile symptoms in old mice via regulation of the AMPK/SIRT1/PGC-1α signaling cascade. Gerontology. 2018;64(5):457–65. doi: 10.1159/000487360 [DOI] [PubMed] [Google Scholar]
  • 18.Wan F, Zhi D, Liu D, Xian J, Li M, AbuLizi A, et al. Lifespan extension in Caenorhabiditis elegans by several traditional Chinese medicine formulas. Biogerontology. 2014;15(4):377–87. doi: 10.1007/s10522-014-9508-1 [DOI] [PubMed] [Google Scholar]
  • 19.Marchese A, Arciola CR, Barbieri R, Silva AS, Nabavi SF, Tsetegho Sokeng AJ, et al. Update on monoterpenes as antimicrobial agents: a particular focus on p-cymene. Materials (Basel). 2017;10(8):947. doi: 10.3390/ma10080947 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Silva LL, Garlet QI, Benovit SC, Dolci G, Mallmann CA, Bürger ME, et al. Sedative and anesthetic activities of the essential oils of Hyptis mutabilis (Rich.) Briq. and their isolated components in silver catfish (Rhamdia quelen). Braz J Med Biol Res. 2013;46(9):771–9. doi: 10.1590/1414-431X20133013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.He P, Zhu D, Man X, Bai Q, Huang L, Shi X, et al. Strengthening of Traditional Chinese Medicine in the health system reform: effect on health outcomes and financial protection. Evid Based Complement Alternat Med. 2022;2022:7226674. doi: 10.1155/2022/7226674 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Burton A, Smith M, Falkenberg T. Building WHO’s global Strategy for Traditional Medicine. Eur J Integr Med. 2015;7(1):13–5. doi: 10.1016/j.eujim.2014.12.007 [DOI] [Google Scholar]
  • 23.Shih Y-H, Chang H-Y, Lu M-I, Hurng B-S. Time trend of prevalence of self-reported cataract and its association with prolonged sitting in Taiwan from 2001 and 2013. BMC Ophthalmol. 2014;14:128. doi: 10.1186/1471-2415-14-128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Shih YT, Hung YT, Chang HY, Liu JP, Lin HS, Chang MC. The design, contents, operation and the characteristics of the respondents of the 2001 National Health Interview Survey in Taiwan. Taiwan J Public Health. 2003;22(6):419–30. [Google Scholar]
  • 25.Chen F-P, Chen T-J, Kung Y-Y, Chen Y-C, Chou L-F, Chen F-J, et al. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res. 2007;7:26. doi: 10.1186/1472-6963-7-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hwang J-S, Hu T-H, Lee LJ-H, Wang J-D. Estimating lifetime medical costs from censored claims data. Health Econ. 2017;26(12):e332–44. doi: 10.1002/hec.3512 [DOI] [PubMed] [Google Scholar]
  • 27.Chiu Y-M, Lu Y-P, Lan J-L, Chen D-Y, Wang J-D. Lifetime risks, life expectancy, and health care expenditures for rheumatoid arthritis: a nationwide cohort followed up from 2003 to 2016. Arthritis Rheumatol. 2021;73(5):750–8. doi: 10.1002/art.41597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Huang C-C, Lin C-N, Chung C-H, Hwang J-S, Tsai S-T, Wang J-D. Cost-effectiveness analysis of the oral cancer screening program in Taiwan. Oral Oncol. 2019;89:59–65. doi: 10.1016/j.oraloncology.2018.12.011 [DOI] [PubMed] [Google Scholar]
  • 29.Kuo S-C, Lin C-N, Lin Y-J, Chen W-Y, Hwang J-S, Wang J-D. Optimal intervals of ultrasonography screening for early diagnosis of hepatocellular carcinoma in Taiwan. JAMA Netw Open. 2021;4(6):e2114680. doi: 10.1001/jamanetworkopen.2021.14680 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wu T-Y, Chung C-H, Lin C-N, Hwang J-S, Wang J-D. Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan. Clin Epidemiol. 2018;10:581–91. doi: 10.2147/CLEP.S155601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lo W-C, Hu T-H, Hwang J-S. Lifetime exposure to PM2.5 air pollution and disability-adjusted life years due to cardiopulmonary disease: a modeling study based on nationwide longitudinal data. Sci Total Environ. 2023;855:158901. doi: 10.1016/j.scitotenv.2022.158901 [DOI] [PubMed] [Google Scholar]
  • 32.Lo W-C, Hu T-H, Shih C-Y, Lin H-H, Hwang J-S. Impact of healthy lifestyle factors on life expectancy and lifetime health care expenditure: nationwide cohort study. JMIR Public Health Surveill. 2024;10:e57045. doi: 10.2196/57045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Li C-L, Hsia T-C, Li C-H, Chen K-J, Yang Y-H, Yang S-T. Adjunctive Traditional Chinese Medicine Improves Survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study. Integr Cancer Ther. 2019;18. doi: 10.1177/1534735419827079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lin Y-S, Shen Y-C, Wu C-Y, Tsai Y-Y, Yang Y-H, Lin Y-Y, et al. Danshen improves survival of patients with breast cancer and Dihydroisotanshinone I induces ferroptosis and apoptosis of breast cancer cells. Front Pharmacol. 2019;10:1226. doi: 10.3389/fphar.2019.01226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kuo Y-T, Chang T-T, Muo C-H, Wu M-Y, Sun M-F, Yeh C-C, et al. Use of complementary traditional chinese medicines by adult cancer patients in Taiwan: A Nationwide Population-Based Study. Integr Cancer Ther. 2018;17(2):531–41. doi: 10.1177/1534735417716302 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Liao Y-H, Lin C-C, Lai H-C, Chiang J-H, Lin J-G, Li T-C. Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients. Liver Int. 2015;35(12):2595–602. doi: 10.1111/liv.12847 [DOI] [PubMed] [Google Scholar]
  • 37.Ding X, Ma X, Meng P, Yue J, Li L, Xu L. Potential effects of traditional Chinese medicine in anti-aging and aging-related diseases: current evidence and perspectives. Clin Interv Aging. 2024;:681–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wang X, Zhang A, Sun H, Wang P. Systems biology technologies enable personalized traditional Chinese medicine: a systematic review. Am J Chin Med. 2012;40(6):1109–22. doi: 10.1142/S0192415X12500826 [DOI] [PubMed] [Google Scholar]
  • 39.Zeng XX, Bian ZX, Wu TX, Fu SF, Ziea E, Woon WTC. Traditional Chinese medicine syndrome distribution in chronic hepatitis B populations: a systematic review. Am J Chin Med. 2011;39(06):1061–74. [DOI] [PubMed] [Google Scholar]
  • 40.Zhang A, Sun H, Wang P, Han Y, Wang X. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach. Complement Ther Med. 2012;20(1–2):93–9. doi: 10.1016/j.ctim.2011.10.007 [DOI] [PubMed] [Google Scholar]
  • 41.Xin B, Mu S, Tan T, Yeung A, Gu D, Feng Q. Belief in and use of traditional Chinese medicine in Shanghai older adults: a cross-sectional study. BMC Complement Med Ther. 2020;20(1):128. doi: 10.1186/s12906-020-02910-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Rybicka M, Zhao J, Piotrowicz K, Ptasnik S, Mitka K, Kocot-Kępska M, et al. Promoting whole person health: Exploring the role of traditional Chinese medicine in Polish healthcare. J Integr Med. 2023;21(6):509–17. doi: 10.1016/j.joim.2023.10.001 [DOI] [PubMed] [Google Scholar]
  • 43.Lam TP. Strengths and weaknesses of traditional Chinese medicine and Western medicine in the eyes of some Hong Kong Chinese. J Epidemiol Community Health. 2001;55(10):762–5. doi: 10.1136/jech.55.10.762 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Dai Z, Liao X, Wieland LS, Hu J, Wang Y, Kim T-H, et al. Cochrane systematic reviews on traditional Chinese medicine: What matters-the quantity or quality of evidence? Phytomedicine. 2022;98:153921. doi: 10.1016/j.phymed.2021.153921 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Yung-Hsiang Chen

18 Sep 2025

Dear Dr. Lo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Thank you for submitting the following manuscript to PLOS ONE. Please revise the manuscript according to the reviewers' comments and upload the revised file.

==============================

Please submit your revised manuscript by  Nov 01 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Yung-Hsiang Chen, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating in your Funding Statement:

“This work was supported by the National Science and Technology Council (Grant number: NSTC112-2314-B-038-073-MY3) in Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

3. Thank you for stating the following in your Competing Interests section:

“The authors have no conflict of interest to report.”

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

This information should be included in your cover letter; we will change the online submission form on your behalf.

4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

Please update your Data Availability statement in the submission form accordingly.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

6. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set.

Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data ) and in the following article: http://www.bmj.com/content/340/bmj.c181.long.

7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

Additional Editor Comments:

Thank you for submitting the following manuscript to PLOS ONE.

Please revise the manuscript according to the reviewers' comments and upload the revised file.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

Reviewer #1: While the study addresses an important public health question regarding Traditional Chinese Medicine (TCM) utilization and its association with mortality and life expectancy, I have major concerns regarding the conceptualization and measurement of the exposure variable, which limit the validity of causal inference.

In the current manuscript, TCM encompasses diverse modalities including herbal medicine, acupuncture, and Tuina (therapeutic massage), which differ substantially in mechanism, intended use, and potential biological impact. Pooling such heterogeneous practices into a single binary or percentage-based measure assumes homogeneity of effect, which is unlikely to be true. This aggregation obscures which component, if any, is responsible for the observed associations, and risks diluting or misattributing effects.

The use of “>20% of outpatient visits in the prior 18 months” as the primary threshold for defining TCM users is arbitrary and lacks empirical justification. This measure does not directly reflect treatment intensity, dose, duration, or quality of TCM received. For example, a patient receiving a few acupuncture sessions could be classified similarly to one on continuous herbal therapy, despite potentially very different physiological effects.

The observed associations may reflect characteristics of individuals who choose TCM, rather than the effects of TCM interventions themselves. TCM users in the cohort were generally younger, healthier, and had more favorable lifestyle factors at baseline. Although IPTW adjustment was employed, unmeasured confounding from health consciousness, diet quality beyond fruit/vegetable intake, social support, and other behavioral factors remains plausible. Regular contact with TCM practitioners may also lead to ancillary benefits (e.g., health advice, stress reduction) unrelated to specific pharmacologic or procedural effects.

Given these limitations, the results should be interpreted cautiously. The study as designed cannot disentangle whether the life expectancy gain is attributable to TCM-specific therapeutic mechanisms or to correlated health behaviors and socio-cultural factors. Current phrasing in the Discussion leans toward causal interpretation, which may overstate the evidence. It is critical to frame the findings as associations and to emphasize the potential role of residual and unmeasured confounding.

Recommendation:

To strengthen the manuscript, I suggest:

- Conducting modality-specific analyses (herbal medicine, acupuncture, Tuina) if feasible.

- Performing sensitivity analyses using alternative TCM exposure thresholds (e.g., 10%, 30%).

- Adjusting for additional markers of health consciousness and healthcare engagement, or employing negative control outcomes to test for unmeasured confounding.

- Revising the Discussion to clearly differentiate between “association” and “causation” and to acknowledge that the observed benefits may reflect characteristics of TCM users rather than TCM per se.

Reviewer #2: 本研究利用台湾全国健康调查和保险数据库�探讨中医药使用对老年人预期寿命和死亡风险的影响。研究设计严谨�样本量大�统计方法先进。研究结果对公共卫生和临床实践具有重要意义。建议稿件经过细微修改后被接受。 使用来自 NHIS 和 NHIRD 的链接数据提供了国家代表性和较长的随访期。应用滚动外推算法来估计终生生存函数�结合治疗加权的逆概率 �IPTW� 来控制混杂因素�展示了方法论的复杂性。中医使用的定义是“过去 18 个月中医门诊就诊占门诊总就诊量的 20% 以上”是一个关键的暴露标准。它将加强手稿提供简短的理由或引用支持这一阈值的相关文献�无论是临床还是方法学。

<Translation performed by Google translate: "This study used the Taiwan National Health Survey and Insurance Database to investigate the impact of TCM use on life expectancy and mortality risk among older adults. The study was rigorously designed, with a large sample size and advanced statistical methods. The findings have important implications for public health and clinical practice. The manuscript was accepted after minor revisions. The use of linked data from the NHIS and NHIRD provided national representativeness and a long follow-up period. The application of a rolling extrapolation algorithm to estimate lifetime survival functions, combined with inverse probability of treatment weighting (IPTW) to control for confounding factors, demonstrates the methodological complexity. The definition of TCM use as "TCM outpatient visits accounting for ≥ 20% of total outpatient visits in the previous 18 months" is a key exposure criterion. Manuscripts would be encouraged to provide brief justification or cite relevant literature supporting this threshold, both clinically and methodologically.">

Reviewer #3: 1.The study employs IPTW, but it is unclear whether extreme weights were addressed. Such weights can compromise stability and validity. Please clarify whether weight stabilization or truncation was applied; if not, provide a rationale.

2.On page 12 of the manuscript, the paragraph beginning with “When analyzing by smoking status, current or former smokers who used TCM had a significantly…” appears to be duplicated. Please revise.

3.This study reports a dose–response relationship between TCM utilization and mortality, expressed as the hazard ratio per 10% increase in TCM use. However, it is not clear whether the analysis assumed a linear relationship. Could the authors clarify if any assessment of non-linearity was performed, for example, using restricted cubic spline models or other approaches? This would help determine whether the association is truly linear or if there are potential threshold or plateau effects.

4.I appreciate the authors’ effort to account for the dynamic nature of TCM utilization using a time-dependent approach, which is appropriate and strengthens the analysis. However, I recommend that the authors provide more methodological details on how the annual proportion of TCM services relative to total outpatient visits was defined and incorporated into the model. Since an individual’s frequency of TCM visits may fluctuate from year to year (e.g., higher in one year and lower in another), it would be helpful to clarify how such variability was handled in the analysis and how the time-varying exposure was formally defined. Clearer reporting of this step would enhance the transparency and reproducibility of the study.

5.The authors may consider conducting additional cause-specific mortality analyses, which could provide further insights into whether the observed association between TCM utilization and overall mortality is attributable to specific causes of death.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Dec 4;20(12):e0337593. doi: 10.1371/journal.pone.0337593.r002

Author response to Decision Letter 1


30 Oct 2025

Dear Editors:

We would like to thank you for your interest in our manuscript entitled “The Impact of Traditional Chinese Medicine Utilization on Life Expectancy and Mortality,” and for inviting us to submit a revised version.

We sincerely appreciate the reviewers’ thoughtful and constructive comments. While we recognize the importance of many of their suggestions, due to the expiration of our approved data access period and constraints in both the scope and format of the available data, we were unable to conduct additional analyses to fully address some of the reviewers’ requests. (The analyses examining the association between TCM use and the incidence of major chronic diseases had been completed previously and were available for reference in this revision.) Nevertheless, we have carefully revised the manuscript to incorporate relevant clarifications and supplementary explanations. In particular, we have refined the discussion and conclusion sections to more appropriately characterize the observed associations and to avoid overstating any causal interpretation.

All modifications in the main text are marked in Track Changes. A detailed, point-by-point response to the reviewers’ comments is also provided. We once again thank the editors and reviewers for their valuable time and insightful feedback, which have greatly improved the quality and clarity of our manuscript.

Thank you for considering our revised submission to PLOS ONE.

Yours sincerely,

Wei-Cheng Lo, PhD, on behalf of all coauthors

Review Comments to the Author

Reviewer #1:

While the study addresses an important public health question regarding Traditional Chinese Medicine (TCM) utilization and its association with mortality and life expectancy, I have major concerns regarding the conceptualization and measurement of the exposure variable, which limit the validity of causal inference.

In the current manuscript, TCM encompasses diverse modalities including herbal medicine, acupuncture, and Tuina (therapeutic massage), which differ substantially in mechanism, intended use, and potential biological impact. Pooling such heterogeneous practices into a single binary or percentage-based measure assumes homogeneity of effect, which is unlikely to be true. This aggregation obscures which component, if any, is responsible for the observed associations, and risks diluting or misattributing effects.

The use of “>20% of outpatient visits in the prior 18 months” as the primary threshold for defining TCM users is arbitrary and lacks empirical justification. This measure does not directly reflect treatment intensity, dose, duration, or quality of TCM received. For example, a patient receiving a few acupuncture sessions could be classified similarly to one on continuous herbal therapy, despite potentially very different physiological effects.

The observed associations may reflect characteristics of individuals who choose TCM, rather than the effects of TCM interventions themselves. TCM users in the cohort were generally younger, healthier, and had more favorable lifestyle factors at baseline. Although IPTW adjustment was employed, unmeasured confounding from health consciousness, diet quality beyond fruit/vegetable intake, social support, and other behavioral factors remains plausible. Regular contact with TCM practitioners may also lead to ancillary benefits (e.g., health advice, stress reduction) unrelated to specific pharmacologic or procedural effects.

Given these limitations, the results should be interpreted cautiously. The study as designed cannot disentangle whether the life expectancy gain is attributable to TCM-specific therapeutic mechanisms or to correlated health behaviors and socio-cultural factors. Current phrasing in the Discussion leans toward causal interpretation, which may overstate the evidence. It is critical to frame the findings as associations and to emphasize the potential role of residual and unmeasured confounding.

Recommendation:

To strengthen the manuscript, I suggest:

1-1 Conducting modality-specific analyses (herbal medicine, acupuncture, Tuina) if feasible.

1-2 Performing sensitivity analyses using alternative TCM exposure thresholds (e.g., 10%, 30%).

1-3 Adjusting for additional markers of health consciousness and healthcare engagement, or employing negative control outcomes to test for unmeasured confounding.

1-4 Revising the Discussion to clearly differentiate between “association” and “causation” and to acknowledge that the observed benefits may reflect characteristics of TCM users rather than TCM per se.

RESPONSE:

We sincerely thank the reviewer for the thoughtful and constructive comments. We fully agree that the conceptualization of TCM exposure and its heterogeneous nature warrant careful interpretation. We have carefully revised the manuscript to address these concerns, as detailed below.

1-1. On the heterogeneity of TCM modalities

We agree that Traditional Chinese Medicine (TCM) encompasses diverse modalities such as herbal medicine, acupuncture, and Tuina, each with distinct therapeutic mechanisms and intended applications. In our study, however, the available dataset did not allow us to clearly disentangle the effects of these individual components. While treatment modality was recorded in the claims data, many participants received multiple types of TCM therapy within overlapping timeframes, making it analytically infeasible to reliably disentangle the effects of individual modalities. We have acknowledged this limitation explicitly in the revised Discussion section, emphasizing that the observed associations reflect overall TCM service utilization rather than specific therapeutic mechanisms.

(please refer to the main text, page 19, lines 368–372)

1-2. On the exposure definition and threshold

We appreciate the reviewer’s concern regarding the arbitrariness of using “>20% of outpatient visits” as the primary threshold for defining TCM users. According to national health insurance statistics, TCM outpatient visits generally account for approximately 10% of all outpatient visits in Taiwan, indicating that most individuals use TCM only occasionally or for specific conditions. Therefore, we adopted a conservative threshold (>20%) to identify individuals for whom TCM use represents a relatively frequent and meaningful component of their overall healthcare utilization, rather than sporadic or supplementary visits. To avoid potential misinterpretation of terminology, we have revised “TCM users” and “non-users” throughout the manuscript to “frequent” and “non-frequent” TCM users, respectively.

In addition, our analyses incorporated dose–response assessments of mortality risk using both categorical and continuous measures of TCM utilization. Specifically, we categorized participants by the proportion of TCM visits (<10%, 10–20%, 20–30%, and ≥30% of outpatient visits) and observed a generally consistent dose–response pattern, with hazard ratios for all-cause mortality of 1.00, 0.89 (0.79–1.01), 1.01 (0.86–1.12), and 0.81 (0.71–0.93), respectively. Moreover, each 10% increase in TCM utilization at baseline was associated with a hazard ratio of 0.98 (95% CI, 0.95–1.01) for mortality, while the time-dependent exposure analysis yielded a similar association (HR 0.95, 95% CI 0.94–0.96). Although not all intermediate categories reached statistical significance, the consistent gradient across both analyses supports the robustness of our findings and alleviates concerns about the arbitrariness of the 20% threshold.

(please refer to the main text, page 7, lines 132–136, and Table 3)

1-3. On potential residual confounding

We fully agree that TCM users may differ from non-users in unmeasured factors such as health consciousness, social support, or health-seeking behaviors, which could contribute to residual confounding. While we cannot entirely rule out such influences, our models incorporated a broad range of covariates related to demographic, socioeconomic, lifestyle, and health status factors, including age, sex, enrollment year, education level, marital status, monthly household income, employment status, smoking, alcohol and betel nut use, physical activity, diet, and major chronic diseases. These adjustments may partly capture the behavioral dimensions of health consciousness, but residual confounding cannot be entirely ruled out. We have further elaborated in the Limitation section that despite extensive covariate adjustment, unmeasured confounding factors may still exist and should be considered when interpreting the findings.

(please refer to the main text, page 19, lines 362–368)

1-4. On interpretation and framing of findings

We appreciate the reviewer’s reminder regarding cautious interpretation. We have carefully revised the manuscript to ensure that all statements refer to associations rather than causal effects. The Discussion and Conclusion now emphasize that this study identifies an association between TCM service utilization and increased life expectancy, but cannot establish causality due to the nature of observational data and unmeasured confounding. We have also highlighted that the results should be interpreted as reflecting characteristics of TCM users, the healthcare context, and possible holistic benefits associated with regular TCM engagement.

(please refer to the main text, page 14-21, lines 273–401)

Reviewer #2:

本研究利用台湾全国健康调查和保险数据库�探讨中医药使用对老年人预期寿命和死亡风险的影响。研究设计严谨�样本量大�统计方法先进。研究结果对公共卫生和临床实践具有重要意义。建议稿件经过细微修改后被接受。 使用来自 NHIS 和 NHIRD 的链接数据提供了国家代表性和较长的随访期。应用滚动外推算法来估计终生生存函数�结合治疗加权的逆概率 �IPTW� 来控制混杂因素�展示了方法论的复杂性。中医使用的定义是“过去 18 个月中医门诊就诊占门诊总就诊量的 20% 以上”是一个关键的暴露标准。它将加强手稿提供简短的理由或引用支持这一阈值的相关文献�无论是临床还是方法学。

<Translation performed by Google translate: "This study used the Taiwan National Health Survey and Insurance Database to investigate the impact of TCM use on life expectancy and mortality risk among older adults. The study was rigorously designed, with a large sample size and advanced statistical methods. The findings have important implications for public health and clinical practice. The manuscript was accepted after minor revisions. The use of linked data from the NHIS and NHIRD provided national representativeness and a long follow-up period. The application of a rolling extrapolation algorithm to estimate lifetime survival functions, combined with inverse probability of treatment weighting (IPTW) to control for confounding factors, demonstrates the methodological complexity. The definition of TCM use as "TCM outpatient visits accounting for ≥ 20% of total outpatient visits in the previous 18 months" is a key exposure criterion. Manuscripts would be encouraged to provide brief justification or cite relevant literature supporting this threshold, both clinically and methodologically.">

RESPONSE:

We appreciate the reviewer’s comment regarding the definition of TCM use. In our study, we defined “TCM users” as those whose TCM outpatient visits accounted for 20% or more of their total outpatient visits over the past 18 months. According to national health insurance data, TCM visits in Taiwan generally account for about 10% of all outpatient visits, suggesting that most individuals use TCM only occasionally or for specific conditions. Thus, we adopted a conservative threshold to identify individuals for whom TCM use represents a relatively frequent and meaningful component of their overall healthcare utilization, rather than sporadic or supplementary visits. To avoid potential misinterpretation of terminology, we have revised “TCM users” and “non-users” throughout the manuscript to “frequent” and “non-frequent” TCM users, respectively.

We acknowledge, as noted in the revised Limitations section, that the available data do not allow us to confirm whether the 20% threshold represents an optimal cutoff across all populations or health conditions, nor whether it holds equivalent meaning across different modalities of TCM therapy (such as herbal medicine, acupuncture, or tuina). Future research with more granular utilization data, including treatment type and intensity, would help refine this classification and identify more precise thresholds for defining frequent TCM use.

(please refer to the main text, page 7, lines 132–136; page 19, lines 372–377)

Reviewer #3:

3-1. The study employs IPTW, but it is unclear whether extreme weights were addressed. Such weights can compromise stability and validity. Please clarify whether weight stabilization or truncation was applied; if not, provide a rationale.

RESPONSE:

We apologize for not clearly describing this analytical detail. In our standard procedure, we addressed extreme values by truncating the weights at the 1st and 99th percentiles—that is, values below the 1st percentile and above the 99th percentile were replaced with the respective cutoff values. This approach helps improve model stability and reduce the influence of extreme weights. We have added this information to the revised Methods section.

(please refer to the main text, page 9, lines 179–181)

3-2. On page 12 of the manuscript, the paragraph beginning with “When analyzing by smoking status, current or former smokers who used TCM had a significantly…” appears to be duplicated. Please revise.

RESPONSE:

We appreciate the reviewer for noticing this error. The duplicated paragraph has been removed in the revised manuscript.

(please refer to the main text, page 12, lines 241–243)

3-3. This study reports a dose–response relationship between TCM utilization and mortality, expressed as the hazard ratio per 10% increase in TCM use. However, it is not clear whether the analysis assumed a linear relationship. Could the authors clarify if any assessment of non-linearity was performed, for example, using restricted cubic spline models or other approaches? This would help determine whether the association is truly linear or if there are potential threshold or plateau effects.

RESPONSE:

We thank the reviewer for this thoughtful suggestion. The current analysis assumes a linear relationship between the proportion of TCM utilization and mortality risk. We acknowledge that potential non-linear associations (e.g., threshold or plateau effects) were not examined in this study and have added this point to the Limitations section. We agree that future analyses using approaches such as restricted cubic splines would provide a more flexible assessment of potential non-linearity.

(please refer to the main text, page 19-20, lines 377–382)

3-4. I appreciate the authors’ effort to account for the dynamic nature of TCM utilization using a time-dependent approach, which is appropriate and strengthens the analysis. However, I recommend that the authors provide more methodological details on how the annual proportion of TCM services relative to total outpatient visits was defined and incorporated into the model. Since an individual’s frequency of TCM visits may fluctuate from year to year (e.g., higher in one year and lower in another), it would be helpful to clarify how such variability was handled in the analysis and how the time-varying exposure was formally defined. Clearer reporting of this step would enhance the transparency and reproducibility of the study.

RESPONSE:

We appreciate this valuable comment. In the time-dependent Cox model, TCM utilization was defined annually as the proportion of TCM outpatient visits relative to the total number of outpatient visits during the previous calendar year. This variable was updated each year throughout follow-up to reflect temporal changes in individual TCM use patterns. We have clarified this definition and modeling procedure in the revised Methods section to enhance transparency and reproducibility.

(please refer to the main text, page 10-11, lines 202–206)

3-5. The authors may consider conducting additional cause-specific mortality analyses, which could provide further insights into whether the observed association between TCM utilization and overall mortality is attributable to specific causes of death.

RESPONSE:

We thank the reviewer for this valuable suggestion. Due to the expiration of our approved data access period, we were unable to conduct additional analyses to fully address this comment. However, in our previously completed analyses, we exam

Attachment

Submitted filename: Point by point response.docx

pone.0337593.s007.docx (28.3KB, docx)

Decision Letter 1

Yung-Hsiang Chen

11 Nov 2025

The Impact of Traditional Chinese Medicine Utilization on Life Expectancy and Mortality

PONE-D-25-39358R1

Dear Dr. Lo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yung-Hsiang Chen, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Congratulations on the acceptance of your manuscript, and thank you for your interest in submitting your work to PLOS ONE.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #2: Yes

Reviewer #3: Yes

**********

Reviewer #2: At this stage, the authors addressed all 19 key points raised by the three reviewers one by one, with a conscientious attitude and substantial changes. The core concerns—exposure heterogeneity, arbitrary threshold, residual confounding, linearity assumption, weight stability, etc.—were all matched in the Response and line numbers were provided for easy checking. Moreover, the wording was toned down and causal statements were made more cautious; for example, “provides compelling evidence” was changed to “suggests an association,” and the conclusion repeatedly emphasizes “observational,” “residual confounding,” and “cannot establish causality,” basically eliminating Reviewer #1’s worry about “over-causal interpretation.” In summary, I recommend acceptance for publication.

Reviewer #3: (No Response)

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Yung-Hsiang Chen

PONE-D-25-39358R1

PLOS ONE

Dear Dr. Lo,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yung-Hsiang Chen

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Supplementary methods.

    (PDF)

    pone.0337593.s001.pdf (141.1KB, pdf)
    S1 Table. ICD codes for baseline comorbidities.

    (PDF)

    pone.0337593.s002.pdf (54.7KB, pdf)
    S2 Table. Hazard Ratios (HRs) and 95% CIs for associations between TCM utilization (frequent user vs. non-frequent user) and risk of major chronic diseases development.

    (PDF)

    pone.0337593.s003.pdf (127.7KB, pdf)
    S3 Table. Hazard Ratios (HRs) and 95% CIs for associations between TCM utilization (per 10% of TCM utilization increase) and risk of major chronic diseases development.

    (PDF)

    pone.0337593.s004.pdf (121.3KB, pdf)
    S1 Data. STROBE checklist cohort.

    (DOC)

    pone.0337593.s005.doc (95.5KB, doc)
    Attachment

    Submitted filename: Point by point response.docx

    pone.0337593.s007.docx (28.3KB, docx)

    Data Availability Statement

    The data used in this analysis are not owned by the authors and therefore cannot be shared publicly. To acquire access to the individual-level data, interested researchers must complete an application form, submit a research proposal, and provide documentation of institutional review board approval to the Health and Welfare Data Science Center, Taiwan (https://dep.mohw.gov.tw/DOS/cp-5119-59201-113.html). The Center will review these materials and grant access to eligible researchers who meet the criteria for accessing confidential data. It should be noted that authorized researchers will be granted access to the data under the same conditions and procedures as the authors.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES